Rs 3,000 Cancer Drug Sold for Rs 27,000: SC Flags Massive Markups
Justice Sandeep Mehta, sitting with Justice Vikram Nath, highlighted the large price gap while hearing petitions concerning drug pricing, including one filed by advocate Kishan Chand Jain. The bench questioned why medicines could not follow a uniform rule capping the maximum retail price at 16 per cent above the price to the retailer, referring to the same margin used under the Drug Price Control Order. The court also questioned why essential medicines should be excluded from the DPCO when medicines and medical devices fall under the Essential Commodities Act. The bench criticised corporate hospitals for requiring patients to purchase medicines exclusively from in-house pharmacies, observing that such practices can leave patients with limited choice. The court also raised concerns about the financial burden created by inflated medicine prices when patients receive treatment under government health schemes, as higher medicine costs can affect public expenditure. The court had raised a similar concern on September 22 regarding a cancer drug supplied to retailers at around Rs 2,700 but reportedly sold to patients for Rs 27,000. Some reports quoted the bench using strong language to describe the pricing practices, while the Solicitor General reportedly described the proposed 16 per cent cap as a logical approach. The court's observations came during the ongoing proceedings and do not by themselves constitute a final ruling on the issue.
- Justice Sandeep Mehta, sitting with Justice Vikram Nath, highlighted the large price gap while hearing petitions concerning drug pricing, including one filed by advocate Kishan Chand Jain.
- The bench questioned why medicines could not follow a uniform rule capping the maximum retail price at 16 per cent above the price to the retailer, referring to the same margin used under the Drug Price Control Order.
- The court also questioned why essential medicines should be excluded from the DPCO when medicines and medical devices fall under the Essential Commodities Act.
- The bench criticised corporate hospitals for requiring patients to purchase medicines exclusively from in-house pharmacies, observing that such practices can leave patients with limited choice.
- The court also raised concerns about the financial burden created by inflated medicine prices when patients receive treatment under government health schemes, as higher medicine costs can affect public expenditure.
- The court had raised a similar concern on September 22 regarding a cancer drug supplied to retailers at around Rs 2,700 but reportedly sold to patients for Rs 27,000.
- Some reports quoted the bench using strong language to describe the pricing practices, while the Solicitor General reportedly described the proposed 16 per cent cap as a logical approach.
- The court's observations came during the ongoing proceedings and do not by themselves constitute a final ruling on the issue.
Justice Sandeep Mehta, sitting with Justice Vikram Nath, highlighted the large price gap while hearing petitions concerning drug pricing, including one filed by advocate Kishan Chand Jain. The bench questioned why medicines could not follow a uniform rule capping the maximum retail price at 16 per cent above the price to the retailer, referring to the same margin used under the Drug Price Control Order. The court also questioned why essential medicines should be excluded from the DPCO when medicines and medical devices fall under the Essential Commodities Act. The bench criticised corporate hospitals for requiring patients to purchase medicines exclusively from in-house pharmacies, observing that such practices can leave patients with limited choice. The court also raised concerns about the financial burden created by inflated medicine prices when patients receive treatment under government health schemes, as higher medicine costs can affect public expenditure. The court had raised a similar concern on September 22 regarding a cancer drug supplied to retailers at around Rs 2,700 but reportedly sold to patients for Rs 27,000. Some reports quoted the bench using strong language to describe the pricing practices, while the Solicitor General reportedly described the proposed 16 per cent cap as a logical approach. The court's observations came during the ongoing proceedings and do not by themselves constitute a final ruling on the issue.
Background Context & Comprehensive Analysis
Over recent quarters, sustained structural shifts and strategic investment across News have generated significant momentum. Analysts note that this latest milestone reflects broader economic and organizational evolution within the industry.
"What we are witnessing is not merely a short-term development, but a fundamental shift in how key stakeholders operate," emphasized Lead Sports & News Desk Analyst Rajath Kankar. "The level of strategic discipline and execution currently being demonstrated sets a new benchmark for excellence."
Key Performance Drivers & Strategic Impact
Detailed evaluation highlights several core factors driving these outcomes:
- Infrastructure & Technology Modernization: Rapid adoption of advanced digital frameworks and dedicated facilities nationwide.
- Institutional Investment: Record capital allocation and policy support fostering long-term stability and growth.
- Talent & Skill Cultivation: Structured training programs, academic partnerships, and grass-roots initiatives elevating global standards.
Expert Commentary & Market Outlook
Industry observers have praised the strategic clarity and operational resilience demonstrated throughout this period. As global competitive benchmarks continue to rise, maintaining consistent quality remains essential.
"Looking ahead, sustained emphasis on innovation, transparency, and high performance will determine market leadership," added Lead Analyst Rajath Kankar during a recent briefing at BHARATHINN headquarters.
Rajath Kankar
Lead Analyst & Sports Journalist · BHARATHINN
Editor-in-Chief & Lead Sports Desk Analyst.
